Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP)

Odiaka, Emeka; Lounsbury, David W.; Jalloh, Mohamed; Adusei, Ben; Diallo, Thierno Amadou; Kane, Papa Moussa Sène; Rockson, Isabella; Okyne, Vicky; Irusen, Hayley; Pentz, Audrey; Makinde, Ifeoluwa; Ajibola, Olalekan Hafees; Petersen, Lindsay N.; McBride, Jo; Petersen, Desiree C.; Mante, Sunny; Agalliu, Ilir; Adebiyi, Akindele Olupelumi; Popoola, Olufemi; Yeboah, Edward D.; Mensah, James E.; Hsing, Ann W.; Fernandez, P.; Aisuodionoe-Shadrach, Oseremen I.; Joffe, Maureen; Singh, Elvira; Gueye, Serigne; Quintana, Yuri; Fortier, Brian; Rebbeck, Timothy R.; Andrews, Caroline

doi:10.1200/jgo.18.00062

Cited by 9 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We excluded men who had any prior cancer diagnoses, except for non-melanoma skin cancer. All centers used common standardized protocols for subjects' recruitment, interviews, and data collection and processing [25,26].…”

Section: Study Population and Recruitmentmentioning

confidence: 99%

Overall and central obesity and prostate cancer risk in African men

Agalliu

Lin

Zhang

et al. 2021

Cancer Causes Control

Self Cite

View full text Add to dashboard Cite

Purpose African men are disproportionately affected by prostate cancer (PCa). Given the increasing prevalence of obesity in Africa, and its association with aggressive PCa in other populations, we examined the relationship of overall and central obesity with risks of total and aggressive PCa among African men.Methods Between 2016 and 2020, we recruited 2,200 PCa cases and 1,985 age-matched controls into a multi-center, hospital-based case-control study in Senegal, Ghana, Nigeria, and South Africa. Participants completed an epidemiologic questionnaire, and anthropometric factors were measured at clinic visit. Multivariable logistic regression was used to examine associations of overall and central obesity with PCa risk, measured by body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR), respectively. Results Among controls 16.4% were obese (BMI ≥ 30 kg/m 2 ), 26% and 90% had WC > 97 cm and WHR > 0.9, respectively. Cases with aggressive PCa had lower BMI/obesity in comparison to both controls and cases with less aggressive PCa, suggesting weight loss related to cancer. Overall obesity

show abstract

Section: Study Population and Recruitmentmentioning

confidence: 99%

Overall and central obesity and prostate cancer risk in African men

Agalliu

Lin

Zhang

et al. 2021

Cancer Causes Control

Self Cite

View full text Add to dashboard Cite

show abstract

“…The MADCaP Consortium is a case–control study of men of African ancestry with PCa and age‐matched controls. 10 , 11 This analysis is restricted to men enrolled in MADCaP at the Chris Hani Baragwanath Academic Hospital (CHBAH) in Soweto, Johannesburg, SA.…”

Section: Methodsmentioning

confidence: 99%

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study

Pumpalova,

Ramakrishnan,

May

et al. 2023

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

BackgroundMen of African descent are disproportionately affected by prostate cancer (PCa), and many have metastatic disease at presentation. In South Africa (SA), androgen deprivation therapy (ADT) is the first‐line treatment for stage IV PCa.ObjectiveTo identify predictors of overall survival (OS) in Black South African men with stage IV PCa treated with ADT.Design, Setting, and ParticipantsMen diagnosed with prostate cancer (3/22/2016–10/30/2020) at Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg, were recruited for the Men of African Descent with Cancer of the Prostate study. We included men with newly diagnosed stage IV PCa treated with ADT who had a prostate‐specific antigen (PSA) level drawn prior to initiation of ADT and had ≥1 PSA drawn ≥12 weeks after ADT start.Outcomes Measures and Statistical AnalysisWe used Kaplan–Meier statistics to estimate OS and Cox regression models to identify predictors of OS.Results and LimitationsOf the 1097 men diagnosed with prostate cancer, we included 153 men with stage IV PCa who received ADT and met PSA requirements. The median age was 68.0 years (interquartile range 64–73 years). Median OS from time of ADT initiation was 3.39 years (95% confidence interval (CI): 3.14%–noncalculable), while biochemical progression‐free survival was 2.36 years (95% CI: 2.03%–3.73%). Biochemical progression (HR 3.52, 95% CI: 1.85%–6.70%), PSA nadir level >4 ng/mL (HR 3.77, 95% CI: 1.86%–7.62%), alkaline phosphatase level at diagnosis >150 IU/dL (HR 3.09, 95% CI: 1.64%–5.83%), and hemoglobin at diagnosis <13.5 g/dL (HR 2.90, 95% CI: 1.28%–6.56%) were associated with worse OS.ConclusionsIn this study, we identified factors associated with poor OS among Black South African men with stage IV PCa treated with ADT. These factors may be useful in identifying patients for upfront treatment escalation, including the use of docetaxel chemotherapy or escalation of therapy at the time of biochemical progression.Patient SummaryIn this study, we found that high alkaline phosphatase level, anemia at diagnosis, and high PSA nadir after initiation of androgen deprivation therapy are associated with worse overall survival among Black South African men treated with androgen deprivation therapy for metastatic prostate cancer.

show abstract

“…Sample acquisition for this retrospective analysis was undertaken within the Men of African Descent and Carcinoma of the Prostate (MADCaP) biospecimen network which is a pan‐African registry of cancer research comprised of recruitment and implementation centers (RICs) in Ghana and Senegal, and monitoring centers in the United States 16 . Upon approval from institutional review board of MADCaP participant sites (National Radiotherapy Oncology and Nuclear Medicine Centre, Korle Bu Teaching Hospital (NRONMC) in Accra, Ghana; Senegal (the Hôpital Général de Grand Yoff); Moffitt Cancer Center in Florida; and University of Pennsylvania health science system [UPHS] in Pennsylvania), tumor samples were identified from the eligible patients and formalin‐fixed paraffin‐embedded specimens (FFPE) were selected for subsequent tissue processing.…”

Section: Methodsmentioning

confidence: 99%

Prostate tumors of native men from West Africa show biologically distinct pathways—A comparative genomic study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Native African men (NAM) experience a disproportionate burden of prostate cancer (PCa) and have higher mortality rates compared to European American men (EAM). While socioeconomic status has been implicated as a driver of this disparity, little is known about the genomic mechanisms and distinct biological pathways that are associated with PCa of native men of African origin. Methods To understand biological factors that contribute to this disparity we utilized a total of 406 multi‐institutional localized PCa samples, collected by Men of African Descent and Carcinoma of the Prostate biospecimen network and Moffitt Cancer Center/University of Pennsylvania Health science system. We performed comparative genomics and immunohistochemistry to identify the biomarkers that are highly enriched in NAM from west Africa and compared them with African American Men (AAM) and EAM. Quantified messenger RNA expression and Median H scores based on immune reactivity of staining cells, were compared using Mann Whitney test. For gene expression analysis, p values were further adjusted for multiple comparisons using false discovery rates. Results Immunohistochemical analysis on selected biomarkers showed a consistent association between ETS related gene (ERG) status and race with 83% of NAM exhibiting tumors that lacked TMPRSS2‐ERG translocation (ERGnegative) as compared to AAM (71%) and EAM (52%). A higher proportion of NAM (29%) were also found to be double negative (ERGnegative and PTENLoss) as compared to AAM (6%) and EAM (7%). NAM tumors had significantly higher immunoreactivity (H‐score) for PSMA, and EZH2, whereas they have lower H‐score for PTEN, MYC, AR, RB and Racemase, (all p < .05). Comparative genomics revealed that NAM had significant transcriptomic variability in AR‐activity score. In pathways enrichment analysis NAM tumors exhibited the enrichment of proinflammatory pathways including cytokine, interleukins, inflammatory response, and nuclear factor kappa B signaling. Conclusions Prostate tumors in NAM are genomically distinct and are characterized by the dysregulation of several biomarkers. Furthermore, these tumors are also highly enriched for the major proinflammatory pathways. These distinct biological features may have implications for diagnosis and response to targeted therapy among Black men, globally.

show abstract

Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP)

Cited by 9 publications

References 18 publications

Overall and central obesity and prostate cancer risk in African men

Overall and central obesity and prostate cancer risk in African men

Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study

Prostate tumors of native men from West Africa show biologically distinct pathways—A comparative genomic study

Contact Info

Product

Resources

About